NCT05533775 2026-03-06
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT04663347 2026-03-03
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT02018861 2023-09-28
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Incyte Corporation
Phase 1/2 Completed
NCT02432274 2023-07-11
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Eisai Inc.
Phase 1/2 Completed